The number of deaths in the US from drug overdoses has dropped for the third year in a row, declining by 14% since 2024.

Topline results from the phase 3 REDUCE 2 trial show that investigational pozdeutinurad effectively lowers serum uric acid in adults with gout.

Morally injurious betrayal experiences are linked to chronic pain intensity and decreased functional mobility among post-9/11 US combat veterans.

A single-session, telehealth pain relief skills class did not help reduce opioid use in adults with chronic pain, though it modestly improved mental health.

Serious infection risk in older adults with RA appears to be driven more by modifiable clinical factors rather than the age at which RA develops.

Response to febuxostat differed based on hyperuricemia subtype in older patients with gout, with the combined subtype linked to the lowest rates of SU target achievement.

The FDA has approved Immgolis and Immgolis Intri (golimumab-sldi), the first interchangeable biosimilars for Simponi and Simponi Aria to treat RA and UC.

Increasing postoperative step counts after inpatient surgery may help lower the risks for complications and readmission.

Pregestationally assessed cardiometabolic biomarkers may help identify women at increased risk for hypertensive disorders of pregnancy.

FDA issues safety alert for expired Amazon Basic Care Levonorgestrel 1.5mg tablets distributed between January 24, 2025 and April 29, 2026.

Abdominal obesity is associated with a higher prevalence and greater severity of menopausal symptoms, according to results of a recent study.

Treatment with semaglutide significantly improves measures of motivation in patients with major depressive disorder.